Literature DB >> 28125075

Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study.

Arezou A Ghazani1,2,3, Nelly M Oliver1,2, Joseph P St Pierre2, Andrea Garofalo3, Irene R Rainville2,4, Elaine Hiller2,4, Daniel J Treacy1,2, Vanesa Rojas-Rudilla5, Sam Wood2, Elizabeth Bair2, Michael Parello2, Franklin Huang2,3, Marios Giannakis2,3, Frederick H Wilson2,3, Elizabeth H Stover2,3, Steven M Corsello2,3, Tom Nguyen2, Huma Q Rana2,4, Alanna J Church6, Carol Lowenstein2, Carrie Cibulskis3, Ali Amin-Mansour3, Jennifer Heng2, Lauren Brais2, Abigail Santos2, Patrick Bauer2, Amanda Waldron2, Peter Lo2, Megan Gorman2, Christine A Lydon2, Marisa Welch2, Philip McNamara2, Stacey Gabriel3, Lynette M Sholl5, Neal I Lindeman5, Judy E Garber2,4, Steven Joffe7, Eliezer M Van Allen1,2,3, Stacy W Gray2, Pasi A Ja Nne2, Levi A Garraway1,2,3, Nikhil Wagle1,2,3.   

Abstract

PURPOSE: Implementing cancer precision medicine in the clinic requires assessing the therapeutic relevance of genomic alterations. A main challenge is the systematic interpretation of whole-exome sequencing (WES) data for clinical care.
METHODS: One hundred sixty-five adults with metastatic colorectal and lung adenocarcinomas were prospectively enrolled in the CanSeq study. WES was performed on DNA extracted from formalin-fixed paraffin-embedded tumor biopsy samples and matched blood samples. Somatic and germ-line alterations were ranked according to therapeutic or clinical relevance. Results were interpreted using an integrated somatic and germ-line framework and returned in accordance with patient preferences.
RESULTS: At the time of this analysis, WES had been performed and results returned to the clinical team for 165 participants. Of 768 curated somatic alterations, only 31% were associated with clinical evidence and 69% with preclinical or inferential evidence. Of 806 curated germ-line variants, 5% were clinically relevant and 56% were classified as variants of unknown significance. The variant review and decision-making processes were effective when the process was changed from that of a Molecular Tumor Board to a protocol-based approach.
CONCLUSION: The development of novel interpretive and decision-support tools that draw from scientific and clinical evidence will be crucial for the success of cancer precision medicine in WES studies.Genet Med advance online publication 26 January 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28125075     DOI: 10.1038/gim.2016.191

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  23 in total

1.  Personalized genomic analyses for cancer mutation discovery and interpretation.

Authors:  Siân Jones; Valsamo Anagnostou; Karli Lytle; Sonya Parpart-Li; Monica Nesselbush; David R Riley; Manish Shukla; Bryan Chesnick; Maura Kadan; Eniko Papp; Kevin G Galens; Derek Murphy; Theresa Zhang; Lisa Kann; Mark Sausen; Samuel V Angiuoli; Luis A Diaz; Victor E Velculescu
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

2.  Precision oncology: an overview.

Authors:  Levi A Garraway; Jaap Verweij; Karla V Ballman
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

Review 3.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

Review 4.  Clinical analysis and interpretation of cancer genome data.

Authors:  Eliezer M Van Allen; Nikhil Wagle; Mia A Levy
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

5.  Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine.

Authors:  Robert C Green; Katrina A B Goddard; Gail P Jarvik; Laura M Amendola; Paul S Appelbaum; Jonathan S Berg; Barbara A Bernhardt; Leslie G Biesecker; Sawona Biswas; Carrie L Blout; Kevin M Bowling; Kyle B Brothers; Wylie Burke; Charlisse F Caga-Anan; Arul M Chinnaiyan; Wendy K Chung; Ellen W Clayton; Gregory M Cooper; Kelly East; James P Evans; Stephanie M Fullerton; Levi A Garraway; Jeremy R Garrett; Stacy W Gray; Gail E Henderson; Lucia A Hindorff; Ingrid A Holm; Michelle Huckaby Lewis; Carolyn M Hutter; Pasi A Janne; Steven Joffe; David Kaufman; Bartha M Knoppers; Barbara A Koenig; Ian D Krantz; Teri A Manolio; Laurence McCullough; Jean McEwen; Amy McGuire; Donna Muzny; Richard M Myers; Deborah A Nickerson; Jeffrey Ou; Donald W Parsons; Gloria M Petersen; Sharon E Plon; Heidi L Rehm; J Scott Roberts; Dan Robinson; Joseph S Salama; Sarah Scollon; Richard R Sharp; Brian Shirts; Nancy B Spinner; Holly K Tabor; Peter Tarczy-Hornoch; David L Veenstra; Nikhil Wagle; Karen Weck; Benjamin S Wilfond; Kirk Wilhelmsen; Susan M Wolf; Julia Wynn; Joon-Ho Yu
Journal:  Am J Hum Genet       Date:  2016-05-12       Impact factor: 11.025

6.  Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.

Authors:  Kasmintan A Schrader; Donavan T Cheng; Vijai Joseph; Meera Prasad; Michael Walsh; Ahmet Zehir; Ai Ni; Tinu Thomas; Ryma Benayed; Asad Ashraf; Annie Lincoln; Maria Arcila; Zsofia Stadler; David Solit; David M Hyman; David Hyman; Liying Zhang; David Klimstra; Marc Ladanyi; Kenneth Offit; Michael Berger; Mark Robson
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

7.  Discovery and saturation analysis of cancer genes across 21 tumour types.

Authors:  Michael S Lawrence; Petar Stojanov; Craig H Mermel; James T Robinson; Levi A Garraway; Todd R Golub; Matthew Meyerson; Stacey B Gabriel; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2014-01-05       Impact factor: 49.962

8.  Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study.

Authors:  Stacy W Gray; Elyse R Park; Julie Najita; Yolanda Martins; Lara Traeger; Elizabeth Bair; Joshua Gagne; Judy Garber; Pasi A Jänne; Neal Lindeman; Carol Lowenstein; Nelly Oliver; Lynette Sholl; Eliezer M Van Allen; Nikhil Wagle; Sam Wood; Levi Garraway; Steven Joffe
Journal:  Genet Med       Date:  2016-02-11       Impact factor: 8.822

9.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors.

Authors:  D Williams Parsons; Angshumoy Roy; Yaping Yang; Tao Wang; Sarah Scollon; Katie Bergstrom; Robin A Kerstein; Stephanie Gutierrez; Andrea K Petersen; Abhishek Bavle; Frank Y Lin; Dolores H López-Terrada; Federico A Monzon; M John Hicks; Karen W Eldin; Norma M Quintanilla; Adekunle M Adesina; Carrie A Mohila; William Whitehead; Andrew Jea; Sanjeev A Vasudevan; Jed G Nuchtern; Uma Ramamurthy; Amy L McGuire; Susan G Hilsenbeck; Jeffrey G Reid; Donna M Muzny; David A Wheeler; Stacey L Berg; Murali M Chintagumpala; Christine M Eng; Richard A Gibbs; Sharon E Plon
Journal:  JAMA Oncol       Date:  2016-05-01       Impact factor: 31.777

10.  Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

Authors:  Eliezer M Van Allen; Nikhil Wagle; Petar Stojanov; Danielle L Perrin; Kristian Cibulskis; Sara Marlow; Judit Jane-Valbuena; Dennis C Friedrich; Gregory Kryukov; Scott L Carter; Aaron McKenna; Andrey Sivachenko; Mara Rosenberg; Adam Kiezun; Douglas Voet; Michael Lawrence; Lee T Lichtenstein; Jeff G Gentry; Franklin W Huang; Jennifer Fostel; Deborah Farlow; David Barbie; Leena Gandhi; Eric S Lander; Stacy W Gray; Steven Joffe; Pasi Janne; Judy Garber; Laura MacConaill; Neal Lindeman; Barrett Rollins; Philip Kantoff; Sheila A Fisher; Stacey Gabriel; Gad Getz; Levi A Garraway
Journal:  Nat Med       Date:  2014-05-18       Impact factor: 53.440

View more
  24 in total

1.  Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival.

Authors:  Jung S Byun; Sandeep K Singhal; Samson Park; Dae Ik Yi; Tingfen Yan; Ambar Caban; Alana Jones; Partha Mukhopadhyay; Sara M Gil; Stephen M Hewitt; Lisa Newman; Melissa B Davis; Brittany D Jenkins; Jorge L Sepulveda; Adriana De Siervi; Anna María Nápoles; Nasreen A Vohra; Kevin Gardner
Journal:  Clin Cancer Res       Date:  2020-01-07       Impact factor: 12.531

2.  Biomarker testing in cancer management- can one size fit all?

Authors:  Lynette M Sholl; Balazs Halmos
Journal:  Br J Cancer       Date:  2022-09-05       Impact factor: 9.075

3.  Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Authors:  Andrew J Aguirre; Jonathan A Nowak; Nicholas D Camarda; Richard A Moffitt; Arezou A Ghazani; Mehlika Hazar-Rethinam; Srivatsan Raghavan; Jaegil Kim; Lauren K Brais; Dorisanne Ragon; Marisa W Welch; Emma Reilly; Devin McCabe; Lori Marini; Kristin Anderka; Karla Helvie; Nelly Oliver; Ana Babic; Annacarolina Da Silva; Brandon Nadres; Emily E Van Seventer; Heather A Shahzade; Joseph P St Pierre; Kelly P Burke; Thomas Clancy; James M Cleary; Leona A Doyle; Kunal Jajoo; Nadine J McCleary; Jeffrey A Meyerhardt; Janet E Murphy; Kimmie Ng; Anuj K Patel; Kimberly Perez; Michael H Rosenthal; Douglas A Rubinson; Marvin Ryou; Geoffrey I Shapiro; Ewa Sicinska; Stuart G Silverman; Rebecca J Nagy; Richard B Lanman; Deborah Knoerzer; Dean J Welsch; Matthew B Yurgelun; Charles S Fuchs; Levi A Garraway; Gad Getz; Jason L Hornick; Bruce E Johnson; Matthew H Kulke; Robert J Mayer; Jeffrey W Miller; Paul B Shyn; David A Tuveson; Nikhil Wagle; Jen Jen Yeh; William C Hahn; Ryan B Corcoran; Scott L Carter; Brian M Wolpin
Journal:  Cancer Discov       Date:  2018-06-14       Impact factor: 39.397

Review 4.  The value of cell-free DNA for molecular pathology.

Authors:  Caitlin M Stewart; Prachi D Kothari; Florent Mouliere; Richard Mair; Saira Somnay; Ryma Benayed; Ahmet Zehir; Britta Weigelt; Sarah-Jane Dawson; Maria E Arcila; Michael F Berger; Dana Wy Tsui
Journal:  J Pathol       Date:  2018-03-12       Impact factor: 7.996

5.  Inherited DNA-Repair Defects in Colorectal Cancer.

Authors:  Saud H AlDubayan; Marios Giannakis; Nathanael D Moore; G Celine Han; Brendan Reardon; Tsuyoshi Hamada; Xinmeng Jasmine Mu; Reiko Nishihara; Zhirong Qian; Li Liu; Matthew B Yurgelun; Sapna Syngal; Levi A Garraway; Shuji Ogino; Charles S Fuchs; Eliezer M Van Allen
Journal:  Am J Hum Genet       Date:  2018-02-22       Impact factor: 11.025

6.  SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine.

Authors:  Jeremy L Warner; Ishaan Prasad; Makiah Bennett; Monica Arniella; Alicia Beeghly-Fadiel; Kenneth D Mandl; Gil Alterovitz
Journal:  JCO Precis Oncol       Date:  2018-05-01

7.  A regulation probability model-based meta-analysis of multiple transcriptomics data sets for cancer biomarker identification.

Authors:  Xin-Ping Xie; Yu-Feng Xie; Hong-Qiang Wang
Journal:  BMC Bioinformatics       Date:  2017-08-23       Impact factor: 3.169

Review 8.  DNA Repair Pathway Alterations in Bladder Cancer.

Authors:  Kent W Mouw
Journal:  Cancers (Basel)       Date:  2017-03-27       Impact factor: 6.639

9.  An integrated clinical and genomic information system for cancer precision medicine.

Authors:  Yeongjun Jang; Taekjin Choi; Jongho Kim; Jisub Park; Jihae Seo; Sangok Kim; Yeajee Kwon; Seungjae Lee; Sanghyuk Lee
Journal:  BMC Med Genomics       Date:  2018-04-20       Impact factor: 3.063

10.  Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.

Authors:  B Hirsch; V Endris; S Lassmann; W Weichert; N Pfarr; P Schirmacher; V Kovaleva; M Werner; I Bonzheim; F Fend; J Sperveslage; K Kaulich; A Zacher; G Reifenberger; K Köhrer; S Stepanow; S Lerke; T Mayr; D E Aust; G Baretton; S Weidner; A Jung; T Kirchner; M L Hansmann; L Burbat; E von der Wall; M Dietel; M Hummel
Journal:  Virchows Arch       Date:  2018-01-27       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.